254 related articles for article (PubMed ID: 25993213)
1. Smoldering multiple myeloma: when to observe and when to treat?
Mateos MV; San Miguel JF
Am Soc Clin Oncol Educ Book; 2015; ():e484-92. PubMed ID: 25993213
[TBL] [Abstract][Full Text] [Related]
2. Smoldering Multiple Myeloma: Who and When to Treat.
Mateos MV; González-Calle V
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):716-722. PubMed ID: 28709797
[TBL] [Abstract][Full Text] [Related]
3. Smoldering multiple myeloma: to treat or not to treat.
Gentile M; Offidani M; Vigna E; Corvatta L; Recchia AG; Morabito L; Martino M; Morabito F; Gentili S
Expert Opin Pharmacother; 2015 Apr; 16(6):785-90. PubMed ID: 25659943
[TBL] [Abstract][Full Text] [Related]
4. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
Mateos MV; Landgren O
Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254
[TBL] [Abstract][Full Text] [Related]
5. The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.
Caers J; Fernández de Larrea C; Leleu X; Heusschen R; Zojer N; Decaux O; Kastritis E; Minnema M; Jurczyszyn A; Beguin Y; Wäsch R; Palumbo A; Dimopoulos M; Mateos MV; Ludwig H; Engelhardt M
Oncologist; 2016 Mar; 21(3):333-42. PubMed ID: 26921288
[TBL] [Abstract][Full Text] [Related]
6. Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics.
Sundararajan S; Kumar A; Korde N; Agarwal A
Curr Hematol Malig Rep; 2016 Apr; 11(2):102-10. PubMed ID: 26894382
[TBL] [Abstract][Full Text] [Related]
7. Advances in the management of asymptomatic myeloma.
Mateos MV
Curr Opin Oncol; 2014 Nov; 26(6):670-6. PubMed ID: 25210868
[TBL] [Abstract][Full Text] [Related]
8. New approaches to smoldering myeloma.
Mateos MV; San Miguel JF
Curr Hematol Malig Rep; 2013 Dec; 8(4):270-6. PubMed ID: 23975678
[TBL] [Abstract][Full Text] [Related]
9. Management of asymptomatic myeloma patients.
Mateos MV
Expert Rev Hematol; 2015 Feb; 8(1):19-27. PubMed ID: 25363073
[TBL] [Abstract][Full Text] [Related]
10. Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma.
González-Calle V; Dávila J; Escalante F; de Coca AG; Aguilera C; López R; Bárez A; Alonso JM; Hernández R; Hernández JM; de la Fuente P; Puig N; Ocio EM; Gutiérrez NC; García-Sanz R; Mateos MV
Leukemia; 2016 Oct; 30(10):2026-2031. PubMed ID: 27133826
[TBL] [Abstract][Full Text] [Related]
11. [Significant changes in diagnostic and therapeutic procedures in smoldering multiple myeloma].
Jurczyszyn A; Olszewska-Szopa M; Skotnicki AB
Przegl Lek; 2015; 72(11):642-8. PubMed ID: 27012123
[TBL] [Abstract][Full Text] [Related]
12. Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study.
Kyle RA; Larson DR; Therneau TM; Dispenzieri A; Melton LJ; Benson JT; Kumar S; Rajkumar SV
Lancet Haematol; 2014 Oct; 1(1):e28-e36. PubMed ID: 25530988
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer.
Muchtar E; Kumar SK; Magen H; Gertz MA
Leuk Lymphoma; 2018 Feb; 59(2):288-299. PubMed ID: 28592156
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
15. Smoldering multiple myeloma.
Gao M; Yang G; Kong Y; Wu X; Shi J
Biomed Res Int; 2015; 2015():623254. PubMed ID: 26000300
[TBL] [Abstract][Full Text] [Related]
16. 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.
Musto P; Engelhardt M; Caers J; Bolli N; Kaiser M; Van de Donk N; Terpos E; Broijl A; De Larrea CF; Gay F; Goldschmidt H; Hajek R; Vangsted AJ; Zamagni E; Zweegman S; Cavo M; Dimopoulos M; Einsele H; Ludwig H; Barosi G; Boccadoro M; Mateos MV; Sonneveld P; Miguel JS
Haematologica; 2021 Nov; 106(11):2799-2812. PubMed ID: 34261295
[TBL] [Abstract][Full Text] [Related]
17. [Clinical courses and risk factors for progression of smoldering multiple myeloma: a nationwide cohort study in Japan].
Takamatsu Y; Muta T
Rinsho Ketsueki; 2015 Aug; 56(8):1005-10. PubMed ID: 26345559
[TBL] [Abstract][Full Text] [Related]
18. Serum test for assessment of patients with Bence Jones myeloma.
Bradwell AR; Carr-Smith HD; Mead GP; Harvey TC; Drayson MT
Lancet; 2003 Feb; 361(9356):489-91. PubMed ID: 12583950
[TBL] [Abstract][Full Text] [Related]
19. Response evaluation and monitoring of multiple myeloma.
Fernández de Larrea C; Delforge M; Davies F; Bladé J
Expert Rev Hematol; 2014 Feb; 7(1):33-42. PubMed ID: 24483347
[TBL] [Abstract][Full Text] [Related]
20. Progress in the Management of Smoldering Multiple Myeloma.
Schmidt TM; Callander NS
Curr Hematol Malig Rep; 2021 Apr; 16(2):172-182. PubMed ID: 33983517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
